Browsing: Novo

Novo Nordisk has received approval for its weight-loss pill, Wegovy, from the European Commission, which has also given the green light for the marketing of a high-dose version of the weight-loss drug as an injection, Novo Nordisk announced in a filing with the stock exchange

July 15 (Reuters) – Novo Nordisk said on Wednesday the European Commission approved its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, making it the first oral GLP-1 weight-loss treatment cleared for use across the European Union

The approval makes Wegovy the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

Bagsværd, Denmark, 15 July 2026 – Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Wegovy® pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet…

Novo Nordisk stock reflects the position of the Danish pharmaceutical group as a global leader in treatments for diabetes and obesity, supported by persistent demand for GLP-1 therapies and insulin products. The company (ISIN DK0062498333) has built a large and diversified portfolio of injectable and oral drugs that target chronic metabolic conditions, and its shares…

The device could cost less than injections, but coverage stays unclear in a US$100 billion GLP-1 market

Novo Nordisk, the owner of the Ozempic and Wegovy GLP-1 drugs, has announced a deal to work with a Californian biotech firm’s on a weight-loss implant

Novo Nordisk stock is closely tied to the company’s position as a global leader in diabetes care and obesity treatments, with its business model built around chronic disease therapies that drive recurring revenue. The company, headquartered in Denmark and listed on the Copenhagen exchange, generates most of its sales from insulin, GLP-1 therapies for type…

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off market rivals